Corrigendum to “TREX1 activators: A novel therapeutic strategy for rheumatoid arthritis management via cfDNA clearance” [Pharmacol. Res. 218 (2025) 107817] (Pharmacological Research (2025) 218, (S1043661825002427), (10.1016/j.phrs.2025.107817))

The Editor was informed by a reader of possible inconsistencies in the Methods section and one Figure legend the article mentioned above. The Macau University of was asked by the Editor to check the integrity of the results sustaining the above referenced article. The Vice-President of the University and Director of the State Key Laboratory of Mechanism and Quality of Chinese Medicine there located has checked the raw data and confirmed in writing to the journal the integrity of the data, concluding that this was a case of clerical error not modifying the interpretation of the results and that no figures (data/images), results text, statistical outputs, or conclusions were found incorrect. He asked the journal to issue an Erratum. Accordingly, the corrected text is now provided. (1) Methods (Sections 4.12) – TREX1 conditional knockout model nomenclature. All instances of “CKO TREX1^−/−” in the relevant Methods sections are corrected to “TREX1^flox/flox”. (2) Methods (Sections 4.6 and 4.12) – AAV dose unit and corresponding legend text. All occurrences of “PFU” describing the AAV dose should be corrected to “vg”, with the per-joint dose stated as in the original text but in vg/joint (i.e., 5 × 10¹⁰ vg per joint). (The wording describing the AAV dose in Results Section 2.5 and the Figure 4 legend should be updated consistently.) (3) Methods (Section 4.12) – Drug dosing units. The following sentence should be included in Section 4.12 for clarity: “PTE was administered at 50 mg/kg/day and BB at 10 mg/kg/day by oral gavage once daily.” (4) Methods (Sections 4.9 and 4.14) – Biospecimen type for cfDNA/cytokines. The term “plasma” appearing in parts of the Methods should be corrected to “serum” in Sections 4.9 and 4.14. All the authors of the article have agreed to the correction; we apologyse for any inconvenience caused to the readers.